Clinical Trials Directory

Trials / Conditions / Tauopathies

Tauopathies

24 registered clinical trials studyying Tauopathies — 8 currently recruiting.

StatusTrialSponsorPhase
Recruiting[18F]NIDF PET Imaging in Tau-related Diseases
NCT07306598
Tianjin Medical University—
RecruitingStudy of Biodistribution, Metabolism, Excretion and Brain Uptake 18F-JSS20-183A
NCT06932809
University of PennsylvaniaEARLY_Phase 1
RecruitingNeurodegenerative Diseases Progression Markers (MARKERS-NDD)
NCT06596746
Casa di Cura San Raffaele Cassino—
RecruitingStudy of Biodistribution, Metabolism, Excretion and Brain Uptake11C-M503
NCT06303921
University of PennsylvaniaEARLY_Phase 1
RecruitingCW2IP2: Imaging and Diagnostic Assessments
NCT06083467
University of PennsylvaniaN/A
RecruitingStudy of Biodistribution, Metabolism, Excretion and Brain Uptake of 11C-HY-2-15
NCT06032026
University of PennsylvaniaEARLY_Phase 1
WithdrawnStudy to Assess the Efficacy of XPro1595 in Patients With Mild Cognitive Impairment With Biomarkers of Inflamm
NCT05321498
Inmune Bio, Inc.Phase 2
TerminatedAn Open-Label Extension of XPro1595 in Patients With Alzheimer's Disease
NCT05522387
Inmune Bio, Inc.Phase 2
CompletedValidation of Blood Biomarkers for Alzheimer's Disease
NCT05427448
University Hospital, MontpellierN/A
RecruitingA Study of Donanemab (LY3002813) in Participants With Early Symptomatic Alzheimer's Disease (TRAILBLAZER-ALZ 5
NCT05508789
Eli Lilly and CompanyPhase 3
UnknownA First-in-Human Study to Assess Single Doses of APNmAb005 in Healthy Participants
NCT05344989
APRINOIA Therapeutics, LLCPhase 1
CompletedA Study of XPro1595 in Patients With Early Alzheimer's Disease With Biomarkers of Inflammation
NCT05318976
Inmune Bio, Inc.Phase 2
CompletedHarmony at Home: A Pilot Telehealth Program for Rural ADRD Caregivers
NCT05202223
Elizabeth K RhodusN/A
CompletedPilot Pragmatic Clinical Trial to Embed Tele-Savvy Into Health Care Systems
NCT05080777
UConn HealthN/A
CompletedA Bridging Study on Efficacy and Safety of [18F]Florbetaben PET for Diagnosis of Alzheimer Disease Subjects in
NCT05527288
Sinotau Pharmaceutical GroupN/A
CompletedA Study to Evaluate the Safety, Tolerability and Immunogenicity of Tau Targeted Vaccines in Participants With
NCT04445831
AC Immune SAPhase 1 / Phase 2
CompletedA Double-Blind, Placebo-Controlled Safety and Efficacy Study of NA-831
NCT03538522
Biomed Industries, Inc.Phase 2
RecruitingTau PET/CT in Various Tau-Related Disease Patients
NCT06690983
Tianjin Medical University—
CompletedTau PET Imaging With 18F-AV-1451 in Subjects With MAPT Mutations
NCT02676843
Columbia UniversityPhase 2
CompletedCNS Tau Kinetics in Healthy Aging and Alzheimer's Disease
NCT03938870
Washington University School of Medicine—
CompletedA Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Study of Intravenously Administered BMS-
NCT02294851
BiogenPhase 1
CompletedEvaluation of [18F]MNI-777 PET as a Marker of Tau Pathology in Subjects With Tauopathies Compared to Healthy S
NCT02103894
Molecular NeuroImagingPhase 1
UnknownThe Long-Term Safety and Efficacy Follow-Up Study of Subjects Who Completed the Phase I Clinical Trial of Neur
NCT01696591
Duk Lyul Na—
CompletedCOMPARATIVE EFFECTIVENESS OF MCI and DEMENTIA TREATMENTS IN A COMMUNITY-BASED DEMENTIA PRACTICE
NCT02860338
Clionsky Neuro Systems Inc.—